Literature DB >> 16567240

Maintenance immunosuppression regimens: conversion, minimization, withdrawal, and avoidance.

Harold Yang1.   

Abstract

A wide choice of drug combinations is available to clinicians for immunosuppression regimens for their kidney transplant patients. Although many protocols have minimized early graft loss, the optimal long-term regimen is unknown. Recent studies clearly showed that cardiovascular death is now the leading cause of graft loss. Strategies must be developed that address this risk while keeping immunologic events low. Transplant physicians have focused on exploring regimens that minimize or avoid the use of corticosteroids. Studies also have started to explore protocols that minimize calcineurin inhibitor therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16567240     DOI: 10.1053/j.ajkd.2005.12.045

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  11 in total

1.  Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants.

Authors:  J D Scandling; S Busque; S Dejbakhsh-Jones; C Benike; M Sarwal; M T Millan; J A Shizuru; R Lowsky; E G Engleman; S Strober
Journal:  Am J Transplant       Date:  2012-03-08       Impact factor: 8.086

2.  Alternatively activated macrophages in the pathogenesis of chronic kidney allograft injury.

Authors:  Yohei Ikezumi; Toshiaki Suzuki; Takeshi Yamada; Hiroya Hasegawa; Utako Kaneko; Masanori Hara; Toshio Yanagihara; David J Nikolic-Paterson; Akihiko Saitoh
Journal:  Pediatr Nephrol       Date:  2014-12-09       Impact factor: 3.714

3.  Twelve-month pancreas graft function significantly influences survival following simultaneous pancreas-kidney transplantation.

Authors:  Andrew S Weiss; Gerard Smits; Alexander C Wiseman
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-30       Impact factor: 8.237

Review 4.  Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies.

Authors:  Andrew Scott Mathis; Gwen Egloff; Hoytin Lee Ghin
Journal:  World J Transplant       Date:  2014-06-24

Review 5.  Use of hematopoietic cell transplants to achieve tolerance in patients with solid organ transplants.

Authors:  Samuel Strober
Journal:  Blood       Date:  2016-01-21       Impact factor: 22.113

6.  Impact of posttransplantation glomerulonephritis on long-term outcome of kidney transplants: single-center 20-year experience.

Authors:  Tung-Min Yu; Mei-Chin Wen; Ming-Ju Wu; Cheng-Hsu Chen; Chi-Hung Cheng; Chi-Yuan Li; Kuo-Hsiung Shu
Journal:  World J Surg       Date:  2012-12       Impact factor: 3.352

Review 7.  Transplantation for the treatment of type 1 diabetes.

Authors:  R Mark Meloche
Journal:  World J Gastroenterol       Date:  2007-12-21       Impact factor: 5.742

8.  Probability, predictors, and prognosis of posttransplantation glomerulonephritis.

Authors:  Worawon Chailimpamontree; Svetlana Dmitrienko; Guiyun Li; Robert Balshaw; Alexander Magil; R Jean Shapiro; David Landsberg; John Gill; Paul A Keown
Journal:  J Am Soc Nephrol       Date:  2009-02-04       Impact factor: 10.121

9.  Evaluation of risk factor management of patients treated on an internal nephrology ward: a pilot study.

Authors:  Gunar Stemer; Sonja Zehetmayer; Rosa Lemmens-Gruber
Journal:  BMC Clin Pharmacol       Date:  2009-09-06

10.  Modulation of allogeneic CD8+ T-cell response by DZNep controls GVHD while preserving hematopoietic chimerism.

Authors:  Jina Wang; Long Li; Ming Xu; Ruiming Rong; Tongyu Zhu
Journal:  Transplantation       Date:  2013-11-15       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.